Letter to the editor T-replete haplo-transplant using high-dose post transplant cyclophosphamide (PTCY) is increasingly used in patients without match related or unrelated donors [1] . However, the presence of donor-specific anti-HLA antibodies (DSA) in the recipient, which may be identified between 10 and 21% of patients, especially in multiparous females, may compromise the success of the procedure [2, 3] . Indeed, DSA have been associated with a high rate of primary graft failure (between 20 and 75%) or poor graft function after the haplo-transplant, despite the use of PTCY [2, 3] In fact, the search for recipient's DSA is the first step to choose the best donor in a haploidentical-setting [4] . Various tests are available to detect anti-HLA class I and II DSA, including solid-phase bead based immunoassays performed on a Luminex platform. Results are expressed as mean fluorescence intensity (MFI). No clear cutoff has been determined, indicating that DSA are likely to cause graft failure [2, 3] . Recently, C1q activation was developed to detect the complement-binding DSA (C1q-positive), which may predict that activation of the complement cascade will be responsible for donor cells destruction and graft rejection. C1q-positive test is generally correlated with high DSA levels and may be more appropriate to predict graft failure. However, only one study reported this result yet without any clear definition of C1q-positivity [5] .
Pre allograft desensitization protocols combine various strategies to avoid graft cell destruction by DSA. They include: direct reduction of the DSA load by plasma exchange (PE), decrease of DSA production by B cells depletion using anti-CD20 monoclonal antibody therapy or plasma cells depletion using bortezomib/dexamethasone, blocking of macrophages Fc receptors by high-dose intravenous (I.V.) immunoglobulin (Ig) therapy, and inhibition of complement activation by C1q clearance through transfusion of donor-derived platelets/leucocytes bearing HLA antigens corresponding to the DSA (buffy coat) or by using the anti-C5a antibody eculizumab. These strategies are mostly partially effective and unfortunately DSA rebound may occur at the time of transplant with no clear established medical care [6] .
Here we report two such rebound cases for whom the use of repeated doses of rituximab as second desensitization may have contributed to the successful engraftment.
Case #1
In January 2016, a 44-year-old female was diagnosed with T-lineage acute lymphoblastic leukemia. Karyotype was not contributive (Fig. 1) . She failed to respond to induction chemotherapy according to the GRAALL-2005 protocol [7] and received a second-line therapy combining nelarabine, etoposide and cyclophosphamide. She again did not respond to the therapy and received a second salvage therapy as part of the phase 1 study with no success. Finally, it was decided, because of her good performance status and young age, to perform a sequential haploidentical transplant with her sister, who was the only donor available.
This 38-year-old sister had O+ blood group and negative CMV serology, while the recipient was O+ and CMV+. Identification of anti-HLA antibodies was performed by single antigen beads assay (LABScreen Single-Antigen, One Lambda, USA). A MFI <2000 was considered as negative. Anti-HLA antibodies were also analysed for their ability of complement (C1q) binding with the use of single antigen bead assays (C1qScreenTM, One Lambda MA). A MFI of >500 was considered positive. The patient was documented with positive anti-B51 (MFI: 15016), antiCw15 (MFI: 15617), anti-DR4 (MFI: 7104) DSA and tested positive for C1q testing for anti-B51 (MFI: 3681) and antiCw15 (MFI: 1294).
The first part of the conditioning regimen was administered between days −19 and −15, then desensitization was performed, combining 5 PE (1 PE per day from days −13 to −9), rituximab 375 mg/m² I.V. on day −9, and Ig I.V. 1 g/ kg on day −8. The patient became thrombocytopenic under 50 Giga/L at the time of the fourth PE. She received platelets transfusion with a good transfusion performance, allowing to perform the fourth and fifth PE thereafter with no difficulty. Finally, the second part of the sequential regimen was administered between days −7 and −2. While the end of desensitization was associated with a decrease of DSA [anti-B51 (MFI: 5081), anti-Cw15 (MFI: 5428), anti-DR4 (MFI: 1981) and anti-DQ8 (MFI: 203)], a DSA rebound was documented on day-2 (anti-B51 (MFI: 7679), anti-Cw15 (MFI: 8659), anti-DR4 (MFI: 4426) and anti-DQ8 (MFI: 710)). It was then decided to perform a total of 3 doses of rituximab 375 mg/m² I.V. each week on days −1, +6 and +13 in order to decrease the DSA level before graft and during aplasia.
Neutrophils recovery was achieved as early as day +21 with full donor whole blood (WB) chimerism (99.8%) at day +30, persisting on days +60 and +100 (WB: 99.9%, CD3 + T cells: 99.9% at both time points). On day +15, anti-B51 (MFI: 2092), anti-Cw15 (MFI: 2190) DSA were still positive, while anti-DR4 (MFI: 1112) and anti-DQ8 (MFI: 454) DSA were negative. At day +21 (time of neutrophil recovery), all DSA were negative (anti-B51 (MFI: 345), anti-Cw15 (MFI: 394), anti-DR4 (MFI: 856) and anti-DQ8 (MFI: 254)). At 4-and 7-months post-transplant, DSA were still negative (anti-B51 (MFI: 66 and 68), anti-Cw15 (MFI: 260 and 164), anti-DR4 (MFI: 669 and 1095) and anti-DQ8 (MFI: 41 and 82)). C1q test was negative (under 100 MFI) at the time of transplant and at day +14. The patient was documented with cytologic and molecular response on day +100. At 16-month post-transplant, the patient is alive in persistent morphologic and molecular remission with no active chronic GVHD nor active infection. However, thrombocytopenia around 80×10 9 /L still persists leading to poor moderate graft function.
Case #2
In April 2016, a 45-year-old female was diagnosed with an acute myeloid leukemia characterized by an EVI-1 mutation on karyotype (Fig. 2) . She received a combination of + cells/kg of recipient was administered at day 0 on 3 August 2016. Non-blastic aplasia was documented at day 0 on myelogram. GVHD prophylaxis consisted of cyclophosphamide 50 mg/kg per day on days +3 and +4, while cyclosporine A and mycophenolate mofetyl were started on day +5 (with G-CSF). Grade-2 acute cutaneous and digestive GVHD occurred at day +21. The evolution was favorable after initiating corticosteroids at 2 mg/kg per day with tapering thereafter. No chronic GVHD occurred. Not surprisingly, CMV reactivation was documented at day +43, controlled by ganciclovir treatment. C1q test was not reported here on the figure considering the number of DSA results. GVHD graft-versushost disease, MFI mean fluorescence intensity, CMV Cytomegalovirus idarubicine and Ara-C as induction chemotherapy and obtained a complete cytologic remission. She then received a consolidation with high-dose Ara-C but no matched donors were available at the end of aplasia. Because the patient was at high risk of early relapse, we decided to perform a haplo-transplant with her brother, the only haplodonor available. This 37-year-old brother had a B+ blood group and a negative CMV serology while the recipient was B+ and CMV+. However, the patient was documented with positive anti-A2 (MFI: 6028) DSA and the result obtained was positive for anti A-2 C1q test (MFI: 24690). We realized the first desensitization by combining 5 PE (1 PE per day from days −13 to −9), rituximab 375 mg/m² I. V. day −8, and Ig I.V. 1 g/kg day −7. Then, the conditioning regimen was administered between days −6 and −1. While desensitization was associated with the decrease of anti-A2 DSA (MFI: 1488), a DSA rebound was documented on day-2 (MFI: 4584) although the C1q test (MFI: 20) was negative. It was then decided to perform a second desensitization with rituximab 375 mg/m² I.V. on day −1, day +6 and day+13 in order to decrease the DSA level before transplant and during aplasia. Neutrophils and platelets (>50×10 9 /L) recoveries were achieved as early as days +16 and day +22, respectively, with full donor whole blood (WB) chimerism (99.8%) at day +30. Anti-A2 DSA were negative at day +15 (MFI: 1160) as well as day +21 (MFI: 198). Unfortunately, relapse was documented at 3-months post-transplant and the patient died 1-month later.
Here we report full engraftment and good graft function in two patients despite DSA rebound at the time of haplotransplant thanks to the second desensitization with rituximab. So far, 78 patients received haplo-transplant with PTCY in our department and only 3 (3.8%) were documented with DSA. None were contraindicated for transplant procedure as they had no other donor available. As expected, all cases were multiparous female. They all received second desensitization with rituximab for DSA rebound at the time of transplant. A third case is not described here as the patient died before engraftment from multiple organ failure (related to sepsis) at day +14. For this patient, anti-B37 DSA rebound was documented two times: first after desensitization (MFI before: 2916; MFI after: 4098) and second after conditioning regimen (MFI: 7852). A decrease of MFI was documented at day +6 (MFI: 4043). Also, C1q test was negative before desensitization and at the time of transplant.
DSA rebound, that is not described in the literature, is expected to occur during its transfer from tissue to plasma. Only one series at our knowledge has reported the successful benefit of second desensitization in case of DSA rebound. PE + I.V. Ig were used and allowed engraftment in the two cases described above [6] . It seems that similar results may be obtained with repeated doses of pre-and post-graft rituximab. The question of whether to perform a second desensitization, while C1q test is negative at the time of transplant is questionable [5] but we did not want to take the risk of graft failure in our patients. We chose rituximab because of easier accessibility compared to PE and because of its properties to reduce DSA production by autologous B cells and to fix C1q or DSA for precluding or clofarabine 30 mg/m² per day from days −6 to −2, cyclophosphamide 14.5 mg/kg days on −6 and −5, and low-dose total body irradiation 2 grays om day −1 (Clo-Baltimore regimen). Fresh peripheral blood stem cells were used as stem cell source and a dose of 7.97 × 10 6 CD34 + cells /kg of recipient was administered at day 0 on 11 August 2016. GVHD prophylaxis consisted of cyclophosphamide 50 mg/kg per day on day + 3 and + 4, while cyclosporine A and mycophenolate mofetyl were started at day + 5 (with G-CSF). Grade-4 acute digestive GVHD occurred at day + 27. The evolution was favorable after initiating corticosteroids at 2 mg/kg per day with tapering thereafter. Not surprisingly, CMV reactivation was documented at day + 39. This infection persisted despite ganciclovir and foscavir treatments, but was controlled by anti-CMV immunoglobulins. Severe hemorrhagic cystitis related to BK virus (BKv) infection occurred also at day + 46 and was treated by cidofovir with partial response. GVHD graft-versus-host disease, MFI mean fluorescence intensity, CMV Cytomegalovirus, BKv BK virus reducing CDC or ADCC against donor stem cells in the early period of graft infusion [8] . However, it is not excluded that decrease of DSA level observed after transplant may have been related to B cell depletion induced by the rituximab administered earlier, the conditioning regimen and/or the immunosuppressive therapy.
In conclusion, these results show that DSA monitoring all over the transplant procedure is required in patients with DSA receiving haplo-transplant, and that DSA rebound is not necessarily pejorative using a second desensitization. This expands the possibility to allograft patients with haplodonor and DSA despite DSA rebound at time of transplant.
